BioNTech SE
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.
What does it do?
BioNTech is a German biotech company best known for co-creating the Pfizer-BioNTech COVID-19 vaccine — one of the first mRNA vaccines ever approved for widespread human use. mRNA vaccines work like a set of instructions that teach your immune system to fight a specific disease, without injecting the actual virus. Beyond COVID, BioNTech is now trying to use that same mRNA technology to build cancer treatments — essentially training your immune system to attack tumour cells the same way it attacked COVID. Think of them as a company that struck gold once and is now using that windfall to bet big on a completely new way to treat cancer.
BioNTech sits at the frontier of one of medicine's most exciting bets: that mRNA technology — proven at mass scale during COVID — can be redirected to fight cancer, which kills roughly 10 million people a year globally. The company has over €17 billion in cash reserves built from COVID vaccine profits, giving it an unusually long runway to fund risky drug development without needing to raise money from investors. If even one of its cancer drugs succeeds in late-stage trials, it could redefine what the company is worth.
How does it make money?
BioNTech's primary revenue stream is still royalties and sales tied to the Pfizer-BioNTech COVID-19 vaccine, Comirnaty, which it splits with its partner Pfizer. In its latest fiscal year, BioNTech reported $2.9 billion in revenue — up slightly from $2.8 billion the prior year — but posted a net loss of $1.1 billion, largely because it is pouring money into research and development for its cancer pipeline. The company does not yet generate meaningful revenue from its cancer drugs, as they are still in clinical trials (the testing phase required before a drug can be sold). Right now, COVID vaccine income is essentially subsidising the cancer research programme.
Why do investors care?
The core investment story is a transition: from a COVID vaccine company with declining core revenue into a diversified oncology (cancer treatment) business with multiple shots on goal. BioNTech has several cancer drugs in Phase III trials — the final and most advanced stage of human testing — including treatments for lung cancer, breast cancer, and others. For this story to work, at least one of those drugs needs to prove it works better than existing treatments and win regulatory approval. The proven mRNA platform gives BioNTech a potential technological edge, but execution risk is high — most drugs in trials never make it to market.
Deep Dive
MemberA full investor briefing on BioNTech SE — history, leadership, risks, and outlook.